Additionally, the HSD17B13 AG, GG, and AG + GG genotypes were higher in healthy controls vs. the MASLD-HCC group (OR 1.70; 95% CI 1.11–2.62; p = 0.01, OR 2.52; 95% CI 1.20–5.31; p = 0.006, and OR 1.82; 95% CI 1.21–2.75; p = 0.002, respectively). Here, HSD17B13 is linked to hepatocellular carcinoma.